Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives
- ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces its CEO and Founder Kathy Lee-Sepsick has met with several members of Congress to discuss the current women's healthcare landscape. Further, Lee-Sepsick is raising awareness of Femasys and the status of its reproductive products in light of the recently announced women's health initiative from the White House. In mid-March President Biden released an executive order, which calls for a $200M investment in research for women's health and a coordinated approach from more than 20 federal government agencies in addition to the $100M investment announced in November 2023.
- 04/18/2024
|
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
- Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025
- 03/28/2024
|
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
- -- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET -- -- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET --
- 03/21/2024
|
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
- -- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate --
- 03/20/2024
|
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
- -- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Court Ruling creates continued anticipation with top-line pivotal data expected to be announced during Q1 2024 --
- 03/06/2024
|
Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
- -- Femasys readies for the commercial launch of FemaSeed ® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) -- -- Femasys to announce top-line data from recently completed pivotal clinical trial for FemaSeed in first quarter 2024 --
- 02/28/2024
|
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
- -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies.
- 02/06/2024
|
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
- ATLANTA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced that it has activated enrollment for its pivotal FemBloc® trial at University of California, Davis (“UC Davis”) Medical Center in Sacramento, California. The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control (the “FINALE” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®. The FDA-approved, multi-center trial is designed to address the high unmet need that exists for women seeking permanent birth control, for whom elective surgery currently remains the only option.
- 01/26/2024
|
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
- - University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in Femasys' earlier FemBloc study -
- 01/23/2024
|
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
- - Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since enrollment began last quarter -
- 12/15/2023
|
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
- -- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys -- -- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys --
- 11/30/2023
|
Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner
- Femasys is a medical device company that offers a suite of minimally invasive reproductive health products for women. The company recently received clearance for its FemaSeed product and plans to launch it in early 2024. Femasys is also developing a device called FemBloc for permanent birth control and a device called FemCerv for cervical tissue biopsy.
- 11/28/2023
|
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
- - Topline results from FemaSeed ® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced completion of enrollment in the LOCAL FemaSeed® pivotal clinical trial, designed to evaluate women undergoing FemaSeed cycles due to male factor infertility. FemaSeed, an intratubal insemination approach that delivers sperm to the fallopian tube where conception occurs is now readying for commercialization.
- 11/28/2023
|
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
- LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally deve.
- 11/15/2023
|
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
- - $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys' lead product candidate, FemBloc ® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech, Inc. (Nasdaq: PMCB) and other healthcare investors. Femasys is creating accessible innovative options for women, as exemplified by its lead product candidate, FemBloc, in late-stage clinical development for permanent birth control and FDA-cleared product, FemaSeed ® for infertility treatment (also approved in Canada).
- 11/15/2023
|
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
- - 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization -
- 11/14/2023
|
5 of the Most Active Penny Stocks Worth Your Precious Time
- Penny stocks can be a treasure trove of investment opportunities, and the list of Most Active Penny Stocks is a good place to start looking. The downside is that many penny stocks are active for no good fundamental reason and have only volatility to offer investors.
- 10/05/2023
|
3 Micro-Cap Stocks Set to Explode Higher
- Underlying prices exhibited a notable cooling trend, providing the Federal Reserve shows evidence of softer inflation. While Americans did indeed spend more on costly gasoline and services during the month, this moderation in other price components underscores the nature of inflationary pressures.
- 10/02/2023
|
Why Is Femasys (FEMY) Stock Up 181% Today?
- Femasys (NASDAQ: FEMY ) stock is rocketing higher on Tuesday following approval from the Food and Drug Administration (FDA) for FemaSeed. FemaSeed is an infertility treatment that delivers sperm directly into a woman's fallopian tube.
- 09/26/2023
|
Why Is Femasys (FEMY) Stock Up 150% Today?
- Shares of biomedical firm Femasys (NASDAQ: FEMY ) more than doubled on Thursday. This followed an important intellectual property (IP) protection announcement.
- 07/27/2023
|
Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now
- After losing some value lately, a hammer chart pattern has been formed for Femasys Inc. (FEMY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 07/03/2023
|
Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
- ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace Hotel in New York, NY.
- 11/21/2022
|
Femasys Inc. to Participate in Upcoming January Investor Conferences
- ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.
- 12/23/2021
|
Femasys Inc. to Present at The MedTech Conference
- ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, “Early-Stage Medtech and Going Public.” The MedTech Conference, an annual event powered by AdvaMed, convenes the world's leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.
- 09/23/2021
|
Femasys Inc. To Join the Russell Microcap® Index
- ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
- 09/20/2021
|
Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer
- -- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys, having previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic, Inc., both medical technology companies focused on women's healthcare. He will be responsible for providing leadership and direction for Femasys' pipeline of clinical development programs.
- 09/01/2021
|
FEMY Stock Increases Over 35% Intraday: Why It Happened
- The stock price of Femasys Inc (NASDAQ: FEMY) increased by over 35% during intraday trading. This is why it happened.
- 07/20/2021
|
Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed
- First in Class Insemination Treatment for Infertility
- 07/20/2021
|
Femasys: Revolutionizing Female Reproduction
- Femasys has the potential to transform both birth control and infertility, both of which are multibillion-dollar markets. The company has received a $50mil investment from Medtronic and more recently, existing investors bought into the IPO.
- 07/15/2021
|
Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO
- NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY) a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. "We are delighted to work with the outstanding team at Femasys in support of their commitment to women's healthcare," said Matthew Mrozinski, a partner in the investment banking group at Chardan.
- 06/21/2021
|
